Purple Biotech (PPBT) has released an update.
Purple Biotech Ltd. has successfully completed the exercise of warrants, generating $2 million in gross proceeds to further finance its oncology pipeline, including the development of novel therapies targeting tumor immune evasion and drug resistance. Investors took advantage of a reduced exercise price to purchase American Depositary Shares, with the company also issuing new unregistered warrants as part of the transaction. These funds are pivotal for advancing clinical trials and general corporate functionality.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
